PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-7.48%
Revenue decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-7.48%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-7.46%
Gross profit decline while Medical - Pharmaceuticals median is 0.14%. Seth Klarman would investigate competitive position.
0.02%
Margin change of 0.02% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.77%
Other expenses change of 13.77% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
0.60%
Operating expenses change of 0.60% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
-6.23%
Total costs reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
6.67%
Interest expense change of 6.67% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
-0.99%
D&A reduction while Medical - Pharmaceuticals median is 0.97%. Seth Klarman would investigate efficiency.
-18.56%
EBITDA decline while Medical - Pharmaceuticals median is 0.12%. Seth Klarman would investigate causes.
-11.98%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-28.32%
Operating income decline while Medical - Pharmaceuticals median is 2.60%. Seth Klarman would investigate causes.
-22.53%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
83.23%
Other expenses change of 83.23% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-24.99%
Pre-tax income decline while Medical - Pharmaceuticals median is 2.83%. Seth Klarman would investigate causes.
-18.93%
Pre-tax margin decline while Medical - Pharmaceuticals median is 12.24%. Seth Klarman would investigate causes.
-23.91%
Tax expense reduction while Medical - Pharmaceuticals median is 2.41%. Seth Klarman would investigate advantages.
-25.47%
Net income decline while Medical - Pharmaceuticals median is 3.25%. Seth Klarman would investigate causes.
-19.45%
Net margin decline while Medical - Pharmaceuticals median is 7.32%. Seth Klarman would investigate causes.
-25.47%
EPS decline while Medical - Pharmaceuticals median is 8.33%. Seth Klarman would investigate causes.
-25.47%
Diluted EPS decline while Medical - Pharmaceuticals median is 8.33%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.04%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.07%. Seth Klarman would investigate strategy.